X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Asia

Roche Vitamin Plant

Yuvraj_pawp by Yuvraj_pawp
8th August 2014
in Asia, Projects

Roche’s latest vitamin plant is located in Taishan (Shanghai) which is in the north eastern part of the Peoples’ Republic of China.

Roche Holding AG opened its new plant for the manufacture of vitamin A as part of its joint venture with the Shanghai Number Six Pharmaceutical Factory. The venture was formed in 1995, and Roche took a 70% stake. Such an arrangement with a local partner is common in emerging markets, where local connections are necessary to secure business, but the domestic companies often lack the technological expertise of multi-nationals. Roche has so far spent an estimated $200 million on various projects in China. Of this, $21 million was originally devoted to Roche Sunve (Shanghai) Vitamin Co Ltd in 1995.

The Shanghai plant is part of Roche’s vitamins and minerals expansion programme. With around 30% of the world’s population estimated to be suffering from some form of vitamin or mineral deficiency, Roche is expecting the market to grow rapidly as more money becomes available from developing countries’ health services. The Chinese market is particularly important in the longer term, and the plant is expected to supply most of its production locally.

VITAMIN PLANT PROJECT

The new vitamin plant commenced production in October 1999, slightly after the expected deadline. The new plant is the largest vitamin A plant in China and was built at a cost of $25 million.

The contract to construct the plant was placed with Hough Worldwide Construction of the US. Hough specialises in projects which involve feed milling technology, such as at the vitamin plant. Hough claims to have been involved in the construction of more than 100 projects in China since 1979 including plants that vary in capacity from five million to 150 tonnes per hour.

For its automation needs, the plant uses a Siemens process control system (brand name SIMATIC PCS 7). This controls the process with over 1,700 inputs and outputs. The contract for the system included SIPART DR controllers, as well as the performance specification, implementation of the user software, testing and commissioning, and training of the plant personnel. The different parts are linked on a Profibus fieldbus.

Roche also owns a vitamin premix plant through a joint venture which was first opened in 1996, and now forms a part of the company’s operations. The premix plant can therefore get material from the commonly owned vitamin plant, giving it a secure and convenient source of supply. The plant complex therefore serves as a good example of economies of scale.

Tags: Asia Pacific
Previous Post

AstraZeneca Solid Forms Production Plant

Next Post

Arzerra (Ofatumumab) for Treatment of Chronic Lymphocytic Leukaemia (CLL)

Related Posts

Indian Pharmaceutical Industry In 2021 And The Road Ahead
Asia

Indian Pharmaceutical Industry In 2021 And The Road Ahead

24th January 2022
Pfizer, Moderna & AstraZeneca - Their COVID-19 vaccine comparison
Asia

India crosses historic one billion COVID-19 vaccine milestone

26th October 2021
Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents
Asia

UAE approves use of Sinopharm vaccine for children aged between 3 and 17 years

5th August 2021
Dr. Reddy’s Laboratories Announces Launch of the Sputnik V vaccine in the Indian Market
Asia

Dr. Reddy’s Laboratories Announces Launch of the Sputnik V vaccine in the Indian Market

17th May 2021
India authorises DRDO's oxygen dependence-lowering drug for Covid-19
Asia

India authorises DRDO’s oxygen dependence-lowering drug for Covid-19

11th May 2021
New dates for MEDICAL FAIR THAILAND with move to 2022
Asia

New dates for MEDICAL FAIR THAILAND with move to 2022

30th April 2021
Next Post

Arzerra (Ofatumumab) for Treatment of Chronic Lymphocytic Leukaemia (CLL)

Latest News

NIH begins study of allergic reactions to Covid-19 vaccines
News

To Treat COVID WHO Approves Monoclonal Antibody Tocilizumab

18th February 2022
Envirotainer introduces the RAP for the future - part of the Releye series
Packaging & Logistic

Envirotainer introduces the RAP for the future – part of the Releye series

14th February 2022
United Cargo Meets Growing Demand for Pharmaceuticals with New TempControl Containers
Packaging & Logistic

Opticooler receives technical approval by Japanese major airlines

14th February 2022
Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease
Press Statements

Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease

14th February 2022
Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
News

Indian Scientists Claim To Design Vaccine For All Variants

9th February 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In